kabutan

K Pharma,Inc.(4896) Summary

4896
TSE Growth
K Pharma,Inc.
631
JPY
+1
(+0.16%)
Dec 5, 12:45 pm JST
4.06
USD
Dec 4, 10:45 pm EST
Result
PTS
outside of trading hours
635.9
Dec 5, 10:55 am JST
Summary Chart Historical News Financial Result
PER
PBR
4.65
Yield
ー%
Margin Trading Ratio
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
630 JPY 4.06 USD
Previous Close Dec 4
630 JPY 4.05 USD
High Dec 5, 9:37 am
646 JPY 4.16 USD
Low Dec 5, 9:03 am
627 JPY 4.04 USD
Volume
18,000
Trading Value
0.01B JPY 0.07M USD
VWAP
635.1 JPY 4.09 USD
Minimum Trading Value
63,100 JPY 406 USD
Market Cap
7.32B JPY 0.05B USD
Number of Trades
100
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
Slightly High
1-Year Average
501
1-Year High Mar 26, 2025
14,294
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 0 375,400
Nov 21, 2025 0 403,600
Nov 14, 2025 0 461,700
Nov 7, 2025 0 457,200
Oct 31, 2025 0 467,700
Company Profile
K Pharma, Inc. engages in the research and development, manufacturing, and sales of pharmaceuticals and regenerative medicine products. The company originated from Keio University.
Sector
Pharmaceuticals
K Pharma, Inc. is a company specializing in the research and development, manufacturing, and sales of pharmaceuticals and regenerative medicine products. The company primarily focuses on the central nervous system disease area, developing both iPS cell-based drug discovery and regenerative medicine businesses. In iPS drug discovery, K Pharma is advancing the development of treatments for intractable diseases such as ALS and Alzheimer's disease. In regenerative medicine, the company is working on developing iPS cell-derived neural progenitor cell transplantation therapies for neurological disorders like spinal cord injury and cerebral infarction. Through collaborations with universities and research institutions, K Pharma commercializes basic research findings and has established a revenue model based on licensing agreements with pharmaceutical companies. The company aims for early clinical application, promoting the development of groundbreaking treatments in areas with high unmet medical needs.